Bridging phenotype and function in bladder cancer using immuno-competent organoids and ex vivo drug screening.

A clear trend emerged, showing that samples with higher PD-1 + infiltration exhibited a substantially greater reduction in viability when treated with the combination therapy compared to chemotherapy alone—specifically, BLC112 TP, BLC112 TC and BLC117 TC showed reductions of approximately 45%, 61% and 68%, respectively, in cell viability with adding Nivolumab.

also in 19,460 other papers